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Alice S Kaanta1,2, Carl Virtanen3, Laura M Selfors2, Joan S Brugge2* and Benjamin G Neel1,3,4*Abstract
Introduction: The mouse mammary gland provides a powerful model system for studying processes involved in
epithelial tissue development. Although markers that enrich for mammary stem cells and progenitors have been
identified, our understanding of the mammary developmental hierarchy remains incomplete.
Methods: We used the MMTV promoter linked to the reverse tetracycline transactivator to induce H2BGFP expression
in the mouse mammary gland. Mammary epithelial cells (MECs) from virgin mice were sorted by flow cytometry for
expression of the mammary stem cell/progenitor markers CD24 and CD29, and H2BGFP. Sorted populations were
analyzed for in vivo repopulation ability, expression of mammary lineage markers, and differential gene expression.
Results: The reconstituting activity of CD24+/CD29+ cells in cleared fat pad transplantation assays was not
distinguished in GFP+ compared to GFP- subpopulations. However, within the CD24+/CD29lo luminal
progenitor-enriched population, H2BGFP+, but not H2BGFP-, MECs formed mammary structures in transplantation
assays; moreover, this activity was dramatically enhanced in pregnant recipients. These outgrowths contained luminal
and myoepithelial mammary lineages and produced milk, but lacked the capacity for serial transplantation.
Transcriptional microarray analysis revealed that H2BGFP+/CD24+/CD29lo MECs are distinct from H2BGFP-/CD24+/CD29lo
MECs and enriched for gene expression signatures with both the stem cell (CD24+/CD29+) and luminal progenitor
(CD24+/CD29lo/CD61+) compartments.
Conclusions: We have identified a population of MECs containing pregnancy-activated multipotent progenitors that are
present in the virgin mammary gland and contribute to the expansion of the mammary gland during pregnancy.
Keywords: Mammary progenitors, Mammary stem cells, Pregnancy, MMTVrtTA, H2BGFPIntroduction
During the lifetime of a female mammal, the mammary
gland undergoes three distinct modes of growth [1]. In
puberty, ductal elongation and branching establish the
overall mammary architecture. After the female has reached
sexual maturity, the mammary gland undergoes cyclic ex-
pansion and regression during the estrus/menstrual cycle.
Pregnancy features dramatic proliferation and alveolar dif-
ferentiation, which are critical for lactation. These processes
are governed by different signals and hormones, and could
involve the activity of different cell types [2,3].* Correspondence: joan_brugge@hms.harvard.edu; bneel@uhnresearch.ca
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reproduction in any medium, provided the orThe ability of the mammary gland to undergo repeated
rounds of proliferation and remodeling in response to
pregnancy was long cited as evidence for the existence
of mammary stem cells. The Visvader and Eaves labora-
tories reported that subpopulations of mammary epithelial
cells (MECs) within the CD24+/CD29+ or CD24+/CD49f+
compartments are capable of forming a fully functional
mammary gland that can be serially transplanted [4,5].
These groundbreaking studies were followed by the
discovery of additional markers for the purification and
characterization of several MEC subtypes [6-9].
Whereas a mammary epithelial stem cell can be defined
by its ability to establish a fully functional mammary tree
in vivo, the identification and characterization of mammary
progenitors (which are defined by their ability to replicate
and differentiate, but not self-renew) require different types
of assays. Lineage-restricted progenitors that differentiateLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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principally using in vitro assays [4-7]. The CD24+/CD29lo
population can be subdivided into populations of luminal
progenitors and differentiated luminal MECs, depending on
the expression or absence of CD61 (β3 integrin), respect-
ively [6]. Luminal epithelial cells with different in vitro
proliferative potential can be distinguished based on CD49b
(α2 integrin) expression; CD24+/CD49b+, but not CD24+/
CD49blo, MECs form colonies on NIH 3T3 feeder cells
[7]. CD14 and c-Kit expression have been used to identify
prospective alveolar progenitors [8,9]. Although it was
reported initially that CD24+/CD29lo and CD24+/CD49flo
MECs are unable to form outgrowths in vivo, more recent
studies have demonstrated that these MECs can form
small, branched mammary structures when co-injected
with Matrigel into mammary fat pads [10,11]. Other groups
transplanted mixed populations and inferred that the
mammary gland contains progenitors that can give rise to
mammary structures of different sizes and morphological
characteristics [12,13].
Another approach to defining the in vivo activity of
mammary stem cells and progenitors is to track MEC
populations by lineage tracing. Van Keymeulen et al.
recently conducted extensive studies of transgenic mice
that inducibly express fluorescent proteins driven by pro-
moters for known mammary lineage markers, including
CK14, CK8 and CK18 [14]. This study provided evidence
for the presence in the adult mammary gland of long-lived,
unipotent luminal and myoepithelial progenitors that could
contribute significantly to mammary gland expansion
during puberty and pregnancy.
Adult stem cells also have been identified using pulse-
chase assays that are based on the ability of stem cells to re-
tain molecular labels significantly longer than bulk cells in
tissues. Such ‘label retention’ is attributed either to slower
cycling of stem cells or to asymmetric distribution of paren-
tal and daughter chromatids to stem cells and their pro-
genitor progeny (the immortal strand hypothesis). Until
recently, most label retention studies had been performed
using DNA-based labels such as bromodeoxyuridine (BrdU)
or tritiated thymidine. Previous reports that used such
methods suggested the existence of label-retaining cells in
the mammary gland that contribute to pregnancy, undergo
mitosis and express steroid hormone receptors [15-17].
The development of transgenic mice expressing histone
2b fused to eGFP (H2BGFP) has permitted the isolation
of live label-retaining cells, including epidermal and
hematopoietic stem cells, by fluorescence-activated cell
sorting (FACS) [18-20]. Using an analogous approach in an
attempt to identify and purify mammary stem cells, we
crossed H2BGFP transgenic mice with a strain expressing
the reverse tetracycline transactivator under the control of
the mouse mammary tumor virus promoter (MMTVrtTA).
We chose this MMTVrtTA line because it reportedlyexpresses tet element-controlled transgenes in all MECs
[21]. We found no evidence that label retention enriches
for mammary stem cell activity, although the length of the
‘chase’ in our experiment might have been insufficient to
isolate a mammary population of interest.
Nevertheless, in control experiments analyzing pubertal
MMTVrtTA/H2BGFP mice, we made the unexpected
discovery that H2BGFP was expressed primarily within the
CD24+/CD29+ and CD24+/CD29lo compartments, which
contain mammary stem cells and progenitors, respectively.
This unusual expression pattern led us to test whether the
H2BGFP+ and H2BGFP- MEC populations had distinct
properties. Using mammary fat pad transplantation assays,
we found that H2BGFP+/CD24+/CD29lo cells contain a
population of multipotent progenitors that give rise to
mammary structures capable of differentiation and lacta-
tion, but which cannot be serially transplanted. The ability
of these cells to produce such structures increases 5- to
10-fold if recipient mice are made pregnant. Therefore,
our data suggest that the mammary glands of virgin pu-
bertal mice contain a population of pregnancy-activated
multipotent mammary progenitor cells.
Methods
Mice
MMTVrtTA mice [21] on FVB background were obtained
from L. Chodosh (Abramson Cancer Institute). H2BGFP
mice [18] in a CD-1 background were provided by E. Fuchs
(Rockefeller University) and backcrossed onto FVB for
a minimum of five generations prior to crossing with
MMTVrtTA mice. To induce transgene expression,
breeders and experimental mice were maintained on
2 mg/ml doxycycline (Research Products International
Corp., Mount Prospect, IL, USA; 50213285). Mouse
colonies were maintained according to federal, state,
and institutional regulations and ethical approval for
this study was obtained by the institutional review boards
of Beth Israel Deaconess Medical Center and Harvard
Medical School, respectively.
Genotyping
Tail biopsies were obtained from transgenic mice, and
dissolved in 0.5 ml tail lysis buffer (10 mM Tris + 100 mM
NaCl + 10 mM EDTA + 0.5% SDS + 1 mg/ml proteinase K)
at 60°C for >4 hours. After proteinase K treatment, 250 μl of
6 M NaCl were added to each sample, which was then
inverted two to three times and incubated on ice for 10
minutes. Samples were centrifuged at 10,000 rpm in a
microfuge for 10 minutes, and supernatants were
added to 650 μl of isopropanol, inverted two to three
times, and then centrifuged at top speed in a microfuge
for 10 minutes. Pellets were air-dried and dissolved in
100 μl H2O. For H2BGFP genotyping, primers were: GFP-F:
5′-GCAAGGGCGAGGAGCTGTTCACC-3′, GFP-R:
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band size 500 base pair (bp). For tet genotyping, primers
were: tTA-F: 5′-CGCTGTGGGGCATTTTACTTTAG-3′, tTA-
R: 5′-CATgTCCAgATCgAAATCgTC-3′, expected band
size 450 bp. Control genotyping PCR (T-cell receptor delta)
primers were: TCRD-F: 5′-CAAATGTTGCTTGTCTGGTG-3′,
TCRD-R: 5′-gTCAgTCgAgTgCACAgTTT-3′, expected
band size 200 bp. All genotyping PCRs were carried out as
follows: 95°C 5 min, 95°C 45 sec, 58°C 45 sec, 72°C 60 sec,
repeat from second 95°C step 25X, 72°C 5 min, 4°C final.
PCR products were resolved on 2% agarose gels.
Mammary gland harvesting and preparation
Mice were sacrificed and mammary glands were harvested.
Lymph nodes were removed from inguinal gland num-
ber 4, mammary tissue was manually minced, placed in
culture medium (DMEM/F12 + 500 ng/ml hydrocorti-
sone + 10 ng/ml EGF + 10 μg/ml insulin + 20 ng/ml chol-
era toxin + 1% Pen/Strep) [4] with 600 U/ml collagenase
and 200 U/ml hyaluronidase, and shaken at 37°C for 1 to
1.5 hrs. Cells from digested tissue were recovered by centri-
fugation and resuspended in a mixture of 0.25% Trypsin-
EDTA (Gibco number 15050-065; Invitrogen, Carlsbad, CA,
USA), 5 mg/ml dispase (Roche 04942078001; Roche, Basel,
Switzerland) and 0.1 mg/ml DNAse (Sigma number D5319;
Sigma-Aldrich, St Louis, MO, USA) for 5 to 7 minutes.
Reactions were quenched with DMEM/F12 + 10% FBS,
and cells were recovered by centrifugation, resuspended in
Tris-buffered 0.64% NH3Cl for 3 minutes on ice, and then
passed sequentially through 100 um and 40 um filters.
Flow cytometry
Single cell suspensions were blocked in FACS buffer (PBS +
2 mM EDTA + 0.1% BSA) containing 1:25 normal rat serum
(eBioscience, Inc., San Diego, CA, USA; 24-5555) and 1:25
anti-mouse FC receptor block (eBioscience 16-0161) for 10
minutes, and stained in FACS buffer containing directly con-
jugated antibodies for 20 minutes. Cells were resuspended in
FACS buffer (containing 1 μg/ml DAPI for viability analysis)
and analyzed on a BD Aria II or FACS Canto II using BD
Aria software (BD Biosciences, San Jose, CA, USA). Anti-
bodies included: CD24•PE (eBioscience 12-0242), CD29•APC
(Biolegend, San Diego, CA, USA; 102215), CD49f•Biotin
(eBioscience 13-0495), CD31•PeCy7 (eBioscience; 25-0311),
CD45•PeCy7 (eBioscience 25-0451),Ter119•PeCy7 (eBioscience
25-5921) and Streptavidin APC-eFluor 780 (eBioscience
47-4317-82). Antibodies were used at the dilutions
recommended by their manufacturer. Single cells were ana-
lyzed after gating out dead (DAPI+), hematopoietic (CD45+,
Ter119+), and endothelial (CD31+) cells.
Antibodies tested in Figure S1 in Additional file 1:
AlCam•PE (eBioscience 12-1661-81), amphiregulin (R&D
Systems, Minneapolis, MN, USA; BAF989), CD14
(eBioscience 13-0141-80), CD24 (eBioscience 13-0242-80),CD44 (eBioscience 13-0441-81), CD49b (eBioscience; 13-
5971-80), CD49f (eBioscience 13-0495), CD55 (eBioscience
12-0559-71), CD61 (eBioscience 13-0611-80), CD86
(eBioscience 13-0862-80), CD138/Syndecan•PE (R&D
FAB2966P), CD164 (R&D BAF3118), c-Kit (eBioscience 13-
1171-81), CXCL16 (R&D BAF503), E-cadherin (eBioscience
13-3249-80), EpCAM (eBioscience 13-5791-80), FGFR2•PE
(R&D FAB684A), IL1R1•PE (R&D FAB7712P), IL33
(R&D BAF3626), Jag1•PE (eBioscience 12-3391-80),
Muc1 (AbCam, Cambridge, UK; ab13970), Osteoactivin
(R&D BAF2330), PRLR (R&D BAF1445), and Sca-1
(eBioscience). Secondary antibodies included: Streptavidin
APC-eFluor 780 (eBioscience 47-4317-82), anti-rabbit
Alexa750 (Invitrogen A-21039).
Mammary fat pad transplants
Sorted cells were counted and resuspended in growth
factor-reduced Matrigel (BD Biosciences, Franklin Lakes,
NJ, USA; 354230). Three-week-old female mice between
10 to 12 g were obtained from Charles River Laboratories,
Wilmington, MA, USA. Mice were anesthetized with 4 mg/
10 g body weight Avertin (Sigma-Aldrich; T48402), and ab-
domens were shaved and cleaned with 70% ethanol and
Betadine. An inverted Y-shaped incision was made along the
thoracic-inguinal region, and the mammary glands were
exposed. The nipple and mammary artery connecting the
number 4 and number 5 glands were cauterized, and the
epithelium was removed from the inguinal (number 4)
mammary glands. The removed epithelium was fixed and
stained with Carmine Alum solution (2 g/l Carmine + 5 g/l
aluminum potassium sulfate) to verify complete clear-
ing. Cells were injected into cleared fat pad pads in 10 μl vol-
umes, using a Hamilton syringe (Hamilton, Reno, NV, USA).
Incisions were closed with wound clips. For pain control, two
doses of 0.5 mg/kg body weight Buprenorphine (Webster
Veterinary, Devens, MA, USA; 07-867-1196) were adminis-
tered in the 24 hrs after surgery. Mammary fat pads were
harvested six weeks after injection, unless pregnancy induc-
tion required an earlier harvest date. Harvested tissues were
either whole-mounted and scored for mammary outgrowths
or dissociated for reanalysis and/or serial transplants [22].
Pregnancy induction
Adult males were housed with post-transplant females three to
four weeks after surgery. Plugs were checked daily to verify
timing of pregnancies. Females were sacrificed and mammary
glands were harvested between days 14 to 20 of the pregnancy.
Whole mounts
Mice were sacrificed, and the number 4 mammary glands
were dissected, spread onto slides, air-dried for 5 minutes
and fixed in methyl Carnoy (1:3:6 glacial acetic acid,
chloroform, methanol) for 4 to 24 hrs. Tissues were
subjected to sequential washes with 100%, 75%, 50%, and
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overnight in Carmine Alum solution. Mammary glands
were dehydrated sequentially in 70% and 100% EtOH,
subjected to two washes with xylenes, and then mounted in
Permount (Thermo Fisher Scientific, Waltham, MA, USA;
SP15-100). Whole mounts were scored and imaged under
a dissecting microscope [22]. All mammary outgrowths
observed by Carmine Alum stain were confirmed by tissue
sectioning and immunostaining.
Statistical analysis
Mammary repopulating unit MRU frequencies were calcu-
lated using the ELDA (extreme limiting dilution analysis)
method (http://bioinf.wehi.edu.au/software/elda/) [23].
RNA analysis
RNA was harvested from sorted cells using the Qiagen
RNeasy Micro Kit (Qiagen, San Diego, CA, USA; 74004),
amplified using the NuGen RNA amplification system, and
analyzed for gene expression on Illumina Whole Genome
Mouse chips (Illumina, Inc., San Diego, CA, USA; WG6
v2r2). Processed arrays were checked for overall quality
using R (v2.10.0) with the Bioconductor [24] and LUMI
packages [25]. Data were imported into GeneSpring (v12.0,
Agilent Technologies, Santa Clara, CA, USA) and normal-
ized with a quantile-based algorithm. Because experimental
samples were collected on two separate dates, a further
batch correction was applied using a parametric empirical
Bayes framework [26]. Pre-filtering was performed to re-
move probes with no expression in any of the groups
under consideration (at least 80% of samples having an ex-
pression value greater than the 20th percentile). Hierarch-
ical cluster diagrams were built using a Pearson centered
distance measure under average linkage rules. Differentially
expressed genes in GFP+ and GFP- CD24+/CD29lo cells
were identified on a re-normalized and filtered subset of
the whole data set using unpaired Student’s t test with
Benjamini and Hochberg false discovery rate (FDR) [27]
multiple testing correction (q <0.05). Microarray data have
been made publicly available at the Gene Expression
Omnibus (www.ncbi.nlm.nih.gov/geo) under the series
identifier GSE42055.
For analysis of mammary subpopulations defined in
Vaillant et al. [28], pre-processed data were downloaded
from the Gene Expression Omnibus (GSE19446, http://
www.ncbi.nlm.nih.gov/geo/) and analyzed using R (v.2.13.1).
Differentially expressed genes in the CD24+/CD29+,
CD24+/CD29lo/CD61+ and CD24+/CD29lo/CD61+ subpop-
ulations were identified using one-way analysis of variance,
post hoc Tukey honestly significant differences tests and a
P value threshold of 0.05. These results were merged with
the differentially expressed genes identified by the GFP+
and GFP- CD24+/CD29lo arrays, using the manufacturers’
unique probe identifiers. A representative single probe pergene was selected by highest variance across the GFP+
and GFP- CD24+/CD29lo samples. Fold-enrichment was
defined as the observed frequency divided by the expected
frequency. Enrichment P values were calculated with the
hypergeometric distribution implemented in the phyper
function in R. The background population set was the
16,245 unique genes that were identified after pre-filtering
the GFP+ and GFP- CD24+/CD29lo data.
qPCR
RNA was harvested from sorted cells using the Qiagen
RNeasy Micro Kit, amplified using the NuGen RNA ampli-
fication system, and labeled using SYBR Green Master Mix
(Applied Biosystems, Foster City, CA, USA; 4309155).
qPCR reactions were performed by using an Applied
Biosystems 7900HT. Primers were: Esr1-F 5′-TGGGCGA
CATTCTTCTCAA-3′, Esr1-R 5′-TGGACCAGAGGTAC
ATCCATT-3′, Prlr-F 5′-GGTTATAGCATGATGACCT
GCAT-3′, Prlr-R 5′- CAGTTCTTCAGACTTGCCC
TTC-3′, Areg-F 5′-GCGAATGCAGATACATCGAG-3′,
Areg-R 5′- CCACACCGTTCACCAAAGTA-3′, Fgfr2-F
5′-GAGCGCTGCCATTCAAGT-3′, Fgfr2-R 5′- TTGC
TGTTGTTACTGCTGTTCC-3′, Muc1-F 5′-CTGTTCA
CCACCACCATGAC-3′, Muc1-R 5′-CTTGGAAGGGC
AAGAAAACC-3′, Wnt5a-F 5′- ACGCTTCGCTTGA
ATTCCT-3′, Wnt5a-R 5′- CCCGGGCTTAATATTC
CAA-3′, Il1R1-F 5′-CGAACCGTGAACAACACAAA-3′,
Il1R1-R 5′- AATCTCCAGCGACAGCAGAG-3′, Cav1-F
5′-ACGACGACGTGGTCAAGATT-3′, Cav1-R 5′-CAC
AGTGAAGGTGGTGAAGC-3′, Robo1-F 5′-CCACCCA
CCAGACAGGAG-3′, Robo1-R 5′-GTATGAGGTGGG
GAAATTGG-3′.
Immunostaining
For tissue sections, mammary glands were fixed in methyl
Carnoy, or, if previously stained with Carmine Alum, first un-
mounted in xylenes. Tissues were paraffin-embedded and sec-
tioned. For antigen retrieval, slides were deparaffinized in
xylenes, and rehydrated in decreasing concentrations of EtOH,
followed by boiling for 20 minutes in 10 mM sodium citrate.
For frozen sections, freshly dissected tissues were mounted in
OCT compound (Sakura Finetek USA, Inc., Torrance, CA,
USA; 4583), flash-frozen in liquid nitrogen and sectioned.
For cytospins, slides and coverslips were fixed in 4%
PFA and rinsed with PBS for staining. Three-dimensional
Matrigel cultures were fixed and stained as described
by Debnath et al. [29]. Primary antibody staining was
performed at 4°C overnight; secondary antibody staining
was performed at room temperature for 1 hr.
Primary antibodies included: cytokeratin 8/TROMA-1
(Developmental Studies Hybridoma Bank TROMA-I-c),
cytokeratin 18 (Covance, Inc., Emeryville, CA, USA;
SIG-3466), cytokeratin 14 (Lifespan Biosciences, Inc.,
Seattle, WA, USA; LS-C22637), p63 (Biolegend 619001),
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(Santa Cruz Biotechnology, Santa Cruz, CA, USA; SC-542),
progesterone receptor (DAKO, Glostrup, Denmark; A0098),
glucocorticoid receptor (Santa Cruz SC-1004), milk
(Nordic Immunological Laboratories, Tilburg, The
Netherlands; RAM/MSP), amphiregulin (Santa Cruz
sc-25436). AlexaFluor™ secondary antibodies were used
for visualization and imaging.
Results
MMTVrtTA induces H2BGFP expression in the mammary
stem cell and progenitor compartments
We expressed H2BGFP in the mouse mammary gland by
crossing mice that carry a tetracycline-inducible H2BGFP
fusion gene [30] to mice expressing the reverse tetracycline
transactivator under the control of the mouse mammary
tumor virus promoter (MMTVrtTA) [21] (Figure S2 in
Additional file 2). To induce H2BGFP expression, breeders
and pups were treated with doxycycline throughout
breeding, pregnancy, lactation, and after weaning until
sacrifice. Mammary glands were harvested from double
transgenic (MMTVrtTA/H2BGFP) virgin females at
four weeks post-partum and analyzed by flow cytometry
and immunostaining.
For flow cytometric analysis, mammary glands were dis-
sociated to single cell suspensions and stained for CD24,
CD29, and CD49f (Figure 1). These markers divided MECs
into the subpopulations (Figure 1b, c) reported previously
[4,5]. As expected, H2BGFP was not detected in mammary
cells from single transgenic or uninduced double transgenic
mice (data not shown). In contrast to a previous report that
this MMTVrtTA transgene drives ubiquitous expression in
MECs [21], H2BGFP expression was detected in only a
fraction (18 ± 3.1%) of MECs from double transgenic mice
(Figure 1a; also see Discussion).
The vast majority of H2BGFP+ MECs were found in either
the mammary stem cell (CD24+/CD29+, CD24+/CD49f+) or
progenitor (CD24+/CD29lo, CD24+/CD49flo) compartments.
Of the H2BGFP+ cells, 47 ± 11% were CD24+/CD29+, while
39 ± 11% were CD24+/CD29lo (n = 10; representative
flow cytometric profile is shown in Figure 1d). Conversely,
55 ± 6.7% of CD24+/CD29+ MECs and 15 ± 4.4% of
CD24+/CD29lo MECs were H2BGFP+, respectively (n = 10;
representative flow cytometric profiles are shown in
Figures 1e, f). Similarly, 36 ± 7.1% of the H2BGFP+ cells
were CD24+/CD49f+ and 50 ± 1.7% were CD24+/CD49flo
(n = 4; representative flow cytometry profile is shown in
Figure 1g), while 46 ± 3.6% of CD24+/CD49f+ MECs and
21 ± 2.7% of CD24+/CD49flo MECs were H2BGFP+ (n = 4;
representative flow cytometric profiles are shown in
Figures 1h, i). Although each subpopulation exhibited
a range of H2BGFP levels, the maximum fluorescence
intensity was higher in the CD24+/CD29lo and CD24+/
CD49flo (progenitor-containing) populations than in theCD24+/CD29+ and CD24+/CD49f+ (stem cell-containing)
compartments (Figure 1e, f, h, i).
To further characterize H2BGFP+ MECs, we also analyzed
the pattern of H2GFP expression in situ. Mammary glands
from four-week-old, doxycycline-induced, MMTVrtTA/
H2BGFP females were sectioned and immunostained for β1
integrin (CD29), CK8, CK14, and p63. Consistent with the
flow cytometry data, H2BGFP was expressed mosaically and
at a range of levels, and the majority of H2BGFP+ cells co-
expressed β1 integrin (Figure 2a). H2BGFP+ MECs were
detected in the basal layer of the ductal tree and in the
cap cells of the terminal end buds (TEB), as well as in the
luminal layer. Moreover, the luminal (CK8+; Figure 2b),
myoepithelial (CK14+; Figure 2c), and basal/cap cell
(p63+; Figure 2d) populations each contained H2BGFP +
MECs (arrowheads). These data are consistent with our
finding that H2BGFP+ cells fall predominantly within the
CD24+/CD29+ and CD24+/CD29lo compartments.
We also examined how H2GFP expression correlated
with the expression of steroid hormone receptors that are
associated with differentiated MEC populations and play
important roles in mammary biology [4,5,31]. Mammary
glands from four-week-old double transgenic mice were
sectioned and immunostained for CK8 to mark the luminal
compartment, along with estrogen receptor (ER) (Figure 3a),
progesterone receptor (PR) (Figure 3b) or glucocorticoid
receptor (GR) (Figure 3c), which activates the MMTV
promoter and is important for mammary proliferation
during pregnancy [32]. In these pubertal mice, most cells
in the ducts and TEBs were ER+ and GR+, and H2BGFP
was co-expressed with ER and GR in some of these cells
(Figure 3a, c, arrowheads). By contrast, H2BGFP+ cells
consistently failed to express PR (Figure 3b).
MMTVrtTA/H2BGFP expression identifies MECs with
differential repopulation activity
The mammary stem cell/progenitor-containing compart-
ments identified by CD24 and CD29 expression are mixed
populations. For example, the CD24+/CD29+ compart-
ment has a MRU frequency of 1/64 [4], and also contains
myoepithelial progenitors [14]. Differential CD61 expres-
sion divides the CD24+/CD29lo compartment into luminal
progenitors (CD24+/CD29lo/CD61+) and mature luminal
cells (CD24+/CD29lo/CD61-), as demonstrated by in vitro
assays [6]. Because MMTVrtTA/H2BGFP expression also
subdivided these populations, we asked whether mammary
stem cells or progenitors could be enriched further based
on H2BGFP. To this end, we tested the repopulating activity
of all four H2BGFP populations (H2BGFP+/CD24+/CD29+,
H2BGFP-/CD24+/CD29+, H2BGFP+/CD24+/CD29lo and
H2BGFP-/CD24+/CD29lo) by injecting limiting dilutions
of FACS-purified cells into the cleared mammary fat pads
of three-week-old mice. Recipients were maintained on
doxycycline to continue transgene induction.
a. b. c.
d. e. f.
g. h. i.
Figure 1 Flow cytometric analysis of MMTVrtTA/H2BGFP expression within the mammary stem cell and progenitor populations. Total
mammary epithelial cell (MEC) population of four-week-old MMTVrtTA/H2BGFP mice, expressing: (a) H2BGFP (b) CD24/CD29 (c) CD24/CD49f.
MMTVrtTA/H2BGFP expression within: (e) the CD24+/CD29+ gate; (f) the CD24+/CD29lo+ gate; (h) the CD24+/CD49f+ gate; and (i) the
CD24+/CD49flo gate. Stem cell marker expression within the H2BGFP+ population: (d) CD24/CD29 (g) CD24/CD49f. H2BGFP, histone 2B-eGFP;
MMTV, mouse mammary tumor virus promoter; rtTA, reverse tetracycline transactivator.
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six weeks post-transplantation, stained with Carmine Alum
to visualize outgrowths and scored for size (Table 1, Figure
S3 in Additional file 3, Table S1 in Additional file 4).
Because some outgrowths were quite small, recipient
fat pads also were sectioned and immunostained for
mammary epithelial markers to verify their mammary
origin and to visualize the structure of all outgrowths.
The MRU frequency of each population was calculated,
using the ELDA method [23,33,34]; similar results
were obtained by assuming single-hit Poisson statistics
(data not shown). In order to increase the size and visi-
bility of the mammary glands, pregnancy was induced
in some recipients, three to four weeks after trans-
plantation. To determine whether pregnancy affected
repopulation, data from virgin and pregnant recipients
were analyzed separately.We found that the repopulation abilities of H2BGFP+/
CD24+/CD29+ and H2BGFP-/CD24+/CD29+ popula-
tions were similar in virgin and pregnant recipients
(Table 1a, b, e, f ) and comparable to established repopula-
tion frequencies for (unfractionated) CD24+/CD29+ cells
[4]. Based on these data, we conclude that MMTVrtTA/
H2BGFP expression in the CD24+/CD29+ compartment
does not label MECs with different repopulating activity.
To determine whether MMTVrtTA/H2BGFP expression
could identify previously unidentified mammary progeni-
tors with in vivo activity, we also tested the H2BGFP+ and
H2BGFP- CD24+/CD29lo populations in transplantation
experiments. Although CD24+/CD29lo MECS were ini-
tially believed to be incapable of in vivo mammary gland
reconstitution [4], other studies have since discovered
that this population can develop mammary outgrowths
upon transplantation, under certain conditions [10,11]
Figure 2 (See legend on next page.)
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Figure 2 Expression of lineage markers in mammary glands of MMTVrtTA/H2BGFP mice. Mammary glands were harvested from
four-week-old double transgenic females treated with doxycycline, sectioned and immunostained for: (a) β1 integrin (b) CK8 (c) CK14 or (d) p63.
Each pair of micrographs depicts ducts (upper) and terminal end buds (lower), at 60× magnification. Note that, as expected, cytoplasmic
(CK8, CK14) and cell surface (β1 integrin) lineage markers do not co-localize with H2BGFP in cells that co-express both proteins; only with p63,
which is a nuclear protein, does co-expression result in co-localization with H2BGFP. In all panels, representative co-expressing cells are indicated
by arrowheads. H2BGFP, histone 2B-eGFP; MMTV, mouse mammary tumor virus promoter; rtTA, reverse tetracycline transactivator.
Figure 3 Expression of steroid hormone receptors in the mammary glands of MMTVrtTA/H2BGFP mice. Mammary glands were harvested from
four-week-old double transgenic females treated with doxycycline, sectioned and immunostained for: (a) estrogen receptor (ER) (b) progesterone receptor
(PR) and (c) glucocorticoid receptor (GR). Micrographs depict ducts (left) and terminal end buds (right) at 60× magnification. Arrowheads indicate
representative co-expressing cells. H2BGFP, histone 2B-eGFP; MMTV, mouse mammary tumor virus promoter; rtTA, reverse tetracycline transactivator.
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Table 1 Limiting dilution transplants of MMTVrtTA/
H2BGFP populations
Population Number
of cells
Number
of glands
MRU frequency
(confidence interval)
Virgin recipients
a. H2GFP+/CD24+/CD29+ 10 3/16 1/105 (70 - 160)
20 5/12
50 3/12
100 6/10
200 9/12
b. H2GFP-/CD24+/CD29+ 10 2/12 1/80 (60 - 130)
20 2/14
50 5/12
100 9/12
200 9/10
c. H2GFP+/CD24+/CD29lo 10 0/14 1/1,600 (500 - 4,900)
20 0/12
50 0/12
100 1/12
200 2/14
d. H2GFP-/CD24+/CD29lo 10 0/14 None
20 0/12
50 0/12
100 0/14
200 0/14
+ Pregnancy
e. H2GFP+/CD24+/CD29+ 10 1/4 1/60 (35 - 100)
20 3/6
50 5/8
100 5/8
200 6/6
f. H2GFP-/CD24+/CD29+ 10 3/8 1/140 (80 - 240)
20 3/6
50 2/8
100 4/8
200 4/8
g. H2GFP+/CD24+/CD29lo 10 1/6 1/350 (160 -790)
20 0/8
50 1/6
100 1/8
200 3/6
h. H2GFP-/CD24+/CD29lo 10 0/6 None
20 0/8
50 0/6
100 0/6
200 0/6
Table 1 Limiting dilution transplants of MMTVrtTA/
H2BGFP populations (Continued)
Virgin Recipients vs. Pregnancy - 2nd Experimental Set
i. H2GFP+/CD24+/CD29lo 10 0/14 1/3,800 (500 - 27,000)
Virgin 20 0/12
50 1/12
100 0/12
200 0/8
j. H2GFP+/CD24+/CD29lo 10 2/12 1/280 (170 - 480)
+Pregnancy 20 2/14
50 4/14
100 4/14
200 4/14
Mammary repopulating ability of H2BGFP+/CD24+/CD29+ (a, e), H2BGFP-/CD24+/
CD29+ (b, f), H2BGFP+/CD24+/CD29lo (c, g, i) and H2BGFP-/CD24+/CD29lo
(d, h, j) populations in virgin mice (a-d, i) and pregnant mice (e-h, j). H2BGFP,
histone 2B-eGFP; MMTV, mouse mammary tumor virus promoter; MRU,
mammary reproducing unit; rtTA, reverse tetracycline transactivator.
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CD29+ cells, the ability of H2BGFP+/CD24+/CD29lo MECs
to give rise to multilineage outgrowths was nearly 5-fold
higher in pregnant (1/350), compared with virgin (1/1,600),
mice (Table 1c, g). Outgrowths from H2BGFP+/CD24+/
CD29lo MECs were much smaller than glands derived from
CD24+/CD29+ cells (Figure S3 in Additional file 3, Table S1
in Additional file 4), but contained all mammary lineages
and were able to produce milk (Figure 4).
H2BGFP+/CD24+/CD29lo MECs give rise to mammary
outgrowths preferentially in pregnant mice
To directly address whether H2BGFP+/CD24+/CD29lo
MECs expand selectively during pregnancy, we performed
an additional set of transplantation experiments (n = 3),
focusing specifically on the H2BGFP+/CD24+/CD29lo
population. Half of the mice injected with H2BGFP+/
CD24+/CD29lo MECs were made pregnant post-transplant
to allow direct comparison of H2BGFP+/CD24+/CD29lo
cell repopulating activity in virgin vs. pregnant mice
(Table 1, bottom). In agreement with the first set of ex-
periments, the MRU frequency of H2BGFP+/CD24+/
CD29lo MECs was 1/280 in pregnant mice, while in virgin
recipients, H2BGFP+/CD24+/CD29lo MECs produced
only a single outgrowth (Table 1i, j). We conclude that
MMTVrtTA-driven expression of H2BGFP in the CD24+/
CD29lo compartment labels a population containing
multipotent stem cells or progenitors that expand pref-
erentially during pregnancy.
H2GFP+/CD24+/CD29lo cells do not self-renew
Stem cells, unlike progenitors, have the ability to self-renew.
In the hematopoietic system, there is a hierarchy of stem
cells with long-term, intermediate-term and short-term
Figure 4 In vivo outgrowth of H2BGFP+/CD24+/CD29 lo cells. Outgrowths from H2BGFP+/CD24+/CD29lo cells were stained with Carmine
Alum for whole-mount analysis, then sectioned and immunostained to analyze their epithelial origin and composition. (a) mammary fat pad
whole mount (b) DAPI, GFP and β1 integrin staining (c) CK8, GFP and p63 staining (d) CK14, GFP and β1 integrin staining (e) DAPI, GFP and
milk staining. Panel b, 10× magnification. Panels c-e, 60× magnification. Arrowheads indicate representative co-expressing cells. DAPI,
4',6-diamidino-2-phenylindole; GFP, green fluorescent protein; H2BGFP, histone 2B-eGFP.
Kaanta et al. Breast Cancer Research 2013, 15:R65 Page 10 of 17
http://breast-cancer-research.com/content/15/4/R65reconstitution ability, respectively [35]. To test whether
MMTVrtTA-driven expression of H2GFP might mark
MECs with differential self-renewal ability, we compared
the serial transplantation ability of the three cell popula-
tions (H2BGFP+/CD24+/CD29+, H2BGFP-/CD24+/CD29+,
and H2BGFP+/CD24+/CD29lo) capable of forming mam-
mary outgrowths. Each MEC population was isolated by
FACS from four-week-old MMTVrtTA/H2BGFP females
and injected in 500-cell aliquots into 10 cleared fat pads of
syngeneic mice. Recipients were treated with doxycycline to
promote H2BGFP expression. After six weeks, transplanted
fat pads were harvested and pooled according to
transplanted cell type, analyzed by flow cytometry, and
re-transplanted. MMTVrtTA/H2BGFP populations were
serially transplanted twice in two experiments, and tertiary
transplants were performed in one experiment.
The H2BGFP+/CD24+/CD29+ and H2BGFP-/CD24+/
CD29+ populations each gave rise to serially transplantable
mammary glands (Figure 5). Surprisingly, only H2BGFP+/
CD24+/CD29+ cells gave rise to mammary glands thatexpressed H2BGFP. To eliminate the possibility that the
apparent H2BGFP-/CD24+/CD29+ outgrowths were the
product of endogenous MECs from incompletely cleared
mammary fat pads, genomic DNA was harvested from
mammary glands after tertiary transplants and tested by
PCR for the MMTVrtTA and H2BGFP transgenes. Both
transgenes were present in H2BGFP+/CD24+/CD29+- and
H2BGFP-/CD24+/CD29+-derived glands, demonstrating
their transgenic origin (data not shown). These results
suggest that H2BGFP expression was repressed perman-
ently in the H2BGFP-/CD24+/CD29+ population. We
conclude that both CD24+/CD29+ populations are capable
of long-term stem cell activity, and H2BGFP expression
within this compartment does not, at least at this level of
analysis, distinguish subpopulations of CD24+/CD29+ cells
with differential biological activity.
By contrast, the H2BGFP+/CD24+/CD29lo popula-
tion was unable to serially transplant, indicating that the
multilineage outgrowths that arise from this compartment
derive from a multipotent progenitor, not a stem cell.
Figure 5 Serial transplants of H2BGFP/CD24/CD29 populations. Flow cytometric analysis of CD24/CD29 (left) and H2BGFP expression (right)
in: (a) wild type control mammary glands; (b) cleared mammary fat pads; and recipients of: (c) H2BGFP+/CD24+/CD29+ cells; (d) H2BGFP-/
CD24+/CD29+ cells; (e) H2BGFP+/CD24+/CD29lo cells; or (f) H2BGFP-/CD24+/CD29lo cells. H2BGFP, histone 2B-eGFP.
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distinct roles for H2BGFP+/CD24+/CD29lo and H2BGFP-/
CD24+/CD29lo populations
The above data provide evidence that H2BGFP+ CD24+/
CD29lo MECs contain a subpopulation of pregnancy-
activated multipotent progenitors. To characterize these
cells further, RNA was isolated from the four MEC
subpopulations of four-week-old mice, and transcrip-
tional profiling was performed using the Illumina
Mouse Microarray platform. Analysis of the resulting
data by unsupervised hierarchical clustering segregated
the samples into subpopulations defined by CD24,
CD29 and H2BGFP expression (Figure 6a). Because we
observed no functional differences between the H2GFP+
and H2GFP- CD24+/CD29+ populations, their failure to
form a separate cluster by unsupervised analysis was not
surprising, and suggests that H2BGFP expression in the
CD24+/CD29+ population is a stochastic phenomenon.By contrast, H2BGFP+/CD24+/CD29lo and H2BGFP-/
CD24+/CD29lo MECs segregated into distinct clusters,
consistent with their different behavior in transplant-
ation experiments.
We focused our subsequent analyses on the gene
expression differences between GFP+ and GFP- CD24+/
CD29lo cells, respectively, and found that 654 probes
(representing 587 unique transcripts) had significantly
(FDR-adjusted P <0.05) different expression levels in these
two populations (Additional file 5). Of these probes, 150
(representing 131 unique transcripts) had a greater
than 2-fold difference. When cross-referenced with
the Gene Ontology database, ten of the differentially
expressed genes were found to be associated with
mammary gland development and differentiation. Each of
these transcripts, except forMucin 1 (Muc1), was expressed
at much lower levels in H2BGFP+/CD24+/CD29lo cells
(Figure 6c and Additional file 6). These included such
Figure 6 (See legend on next page.)
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Figure 6 Gene expression differences segregate MMTVrtTA/H2BGFP MECs into distinct subpopulations. (a) Gene expression data from
the four MMTVrtTA/H2BGFP populations were analyzed using an unsupervised two-way hierarchical clustering of 35,927 filtered probes on the
Illumina Mouse Whole Genome (WG-6 version 2 release 2) microarray. Samples in the CD29+CD24- populations can be seen to segregate into
two distinct subpopulations based on the H2BGFP marker, whereas H2BGFP does not affect the clustering of CD29+CD24+ samples. (b-d)
Differentially expressed genes between the H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations were compared with those found in
a publicly available data set [36] consisting of isolated mammary stem cell-enriched (MaSC), luminal progenitor (lum prog) and mature luminal
mammary epithelial cell (lum mature MEC) populations. The resulting 247 genes in common were plotted as a heat map (b). Ten genes (c) were
chosen for further validation and follow-up analyses based on their association with mammary gland development and differentiation. (d)
Validation of eight of these genes by quantitative RT-PCR. H2BGFP, histone 2B-eGFP; MMTV, mouse mammary tumor virus promoter; rtTA, reverse
tetracycline transactivator.
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ment as the Estrogen receptor 1 (Esr1), Fibroblast growth
factor receptor 2 (Fgfr2), Prolactin receptor (Prlr), and
Amphiregulin (Areg) genes. To validate these observations,
mRNA from H2BGFP+/CD24+/CD29lo and H2BGFP-/
CD24+/CD29lo MECs was analyzed by qPCR (Figure 6d).
These assays confirmed the microarray data for eight of
the ten mammary developmental genes: Areg, Caveolin 1
(Cav1), Esr1, Fgfr2, Mucin 1 (Muc1), Prlr, Roundabout
homolog 1 (Robo1) and Wingless-type MMTV integration
site family, member 5A (Wnt5a). In addition, MMTVrtTA/
H2BGFP MECs from each of the four populations were
cytospun onto slides and immunostained for proteins
whose transcripts were expressed differentially in the
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo
populations and for mammary lineage markers (Figure S4
in Additional file 7). Again, higher levels of Areg and Esr1
were found in H2BGFP-/CD24+/CD29lo MECs than in
H2BGFP+/CD24+/CD29lo MECs.
We next compared the gene expression profiles of the
H2GFP+/CD24+/CD29lo cells and three mammary cell
subpopulations defined by Shackleton et al. [4] and Vaillant
et al. [28], and characterized by Lim et al. [36]: mammary
stem-cell enriched (MaSC) (CD24+/CD29e/CD61+), luminal
progenitor (CD24+/CD29lo/CD61+), and mature luminal
(CD24+/CD29+/CD61-) cells (Figure 6b). Differentially
expressed genes in H2BGFP+/CD24+/CD29lo and H2BGFP-/
CD24+/CD29lo MECs were enriched for genes that dis-
tinguish the CD24+/CD29+, CD24+/CD29lo/CD61+ and
CD24+/CD29e/CD61+ subpopulations (P = 1.07e-06).
Transcripts expressed at higher levels in H2BGFP-/
CD24+/CD29lo cells (compared with H2GFP-/CD24e/
CD29lo cells) were 2.8-fold enriched for genes that were
expressed highly in CD24+/CD29lo/CD61+ MECs, at lower
levels in CD24+/CD29lo/CD61- mature cells and at low-
est levels in the CD24+/CD29+ stem cell compartment
(P = 9.91e-08). The transcripts expressed at higher levels
in H2BGFP+/CD24+/CD29lo MECs also were 2.8-fold
enriched for genes expressed highly in the stem cell
compartment, at lower levels in the CD24e/CD29lo/
CD61+ population, and at lowest levels in the mature
luminal cells (P = 8.75e-06).Although these data indicate that H2BGFP+/CD24+/
CD29lo cells are more similar to CD24+/CD29lo/CD61+
MECs than to CD24+/CD29lo/CD61- MECs, most notably
in their lower levels of transcripts for mammary develop-
mental genes such as Areg, Esr1, Fgfr2 and Prl, H2BGFP
expression in the CD24+/CD29lo population did not correl-
ate with CD61 expression (Figure S1 in Additional file 1).
Therefore, H2BGFP+/CD24+/CD29lo cells share tran-
scriptional characteristics with mammary stem cells
and luminal-restricted progenitors, a phenotype that
might be predicted for a multipotent progenitor, but
one clearly distinct from the CD24+/CD29+ and CD24+/
CD29lo/CD61+ populations.
Discussion
We have identified and characterized a MEC population
with properties of a pregnancy-activated multipotent
progenitor. By studying mammary development in
MMTVrtTA/H2BGFP transgenic mice, we discovered a
subset of CD24+/CD29lo cells possessing the unique abil-
ity to develop small, multilineage mammary outgrowths,
ranging in size from a small alveolar cluster to a half-
grown mammary gland, that can produce milk, yet have
no self-renewal activity. The ability of these cells to form
glandular outgrowths increases 5- to 10-fold when recipient
mice are made pregnant. Transcriptional profiling pro-
vides additional evidence that the H2BGFP+ and H2GFP-
CD24+/CD29lo populations are biologically distinct, with
H2GFP+ cells expressing lower levels of key transcripts
involved in mammary differentiation and higher levels of
transcripts found in the CD24+/CD29+, mammary stem
cell-enriched, compartment.
These H2BGFP+/CD24+/CD29lo MECs are identifiable
in mice in early puberty, which suggests that they arise
during or before pubertal development and remain dor-
mant until pregnancy. The ability of these progenitors to
give rise to mammary outgrowths three to four weeks
after they are transplanted also is consistent with an ability
to remain dormant until activated by pregnancy stimuli.
Our observation that MMTVrtTA is active in mammary
stem cells and pregnancy-activated progenitors conflicts
with a previous report that the same strain of MMTVrtTA
Kaanta et al. Breast Cancer Research 2013, 15:R65 Page 14 of 17
http://breast-cancer-research.com/content/15/4/R65is expressed homogeneously in all MECs [21]. In that
study, the MMTVrtTA transgene-induced expression of
tetracycline-driven LacZ, and an enzymatic assay was used
to detect transgene expression. The enzymatic LacZ assay
is probably more sensitive than flow cytometric detection
of H2BGFP. Moreover, if the β-galactosidase reaction was
not in the linear range in the earlier experiments, it might
not have differentiated between levels of protein expression,
resulting in the erroneous conclusion that MMTVrtTA
transgene activity was uniform in the mammary gland. In
any event, the interpretation of studies that assumed that
this MMTVrtTA strain directs transgene expression ‘uni-
formly’ in the mammary gland should be reconsidered in
light of our data that expression is largely restricted to stem
cells and progenitors.
The molecular basis for selective MMTV-driven label-
ing of stem cells and pregnancy-activated progenitors re-
mains to be elucidated. In separate experiments, wherein
the H2BGFP strain was crossed to other rtTA transgenic
mice, H2BGFP expression was found in significantly fewer
MECs and did not correlate with specific mammary line-
ages (data not shown). Therefore, the pattern of H2BGFP
expression observed in our study appears to be determined
by the MMTVrtTA transgene.
The MMTV promoter contains PR and GR binding
sites, and mammary development during pregnancy is
regulated by progesterone and glucocorticoids, suggesting
a possible mechanism behind MMTV activity in the
mouse mammary gland; however, we found no correlation
between H2BGFP expression and PR or GR expression. Al-
ternatively, the insertion site of this particular MMTVrtTA
transgene could underlie the expression pattern observed
in this study.
Some investigators have hypothesized that mammary
stem cells, rather than progenitors, are activated during
pregnancy for alveoli production [37,38]. Others, however,
suggest that the establishment of the mammary architec-
ture of pregnancy utilizes a process distinct from the prolif-
eration of puberty and estrus, involving the activity of
different cell types [39,40]. Wagner et al. suggested the exist-
ence of pregnancy-activated progenitors by using WAP-Cre
transgenic mice in combination with a Rosa26-lox-lacZ
allele to tag MECs in pregnant glands [40]. After an
initial pregnancy to activate the WAP-Cre transgene,
lineage tracing was used to identify a population of
pregnancy-initiated MECs (PI-MECs) that could give
rise to alveoli in successive pregnancies. These cells
also could form fully functional mammary glands and
were found subsequently to be CD24+/CD49f+ [41,42],
leading these authors to conclude that PI-MECs represent
a mixed population of alveoli-forming progenitors and
stem cells. Our H2BGFP+/CD24+/CD29- cells, by contrast,
do not give rise to serially transplantable mammary
outgrowths, demonstrating that this population lacksmammary stem cells. Because we did not trace the dy-
namics of H2BGFP+/CD24+/CD29lo MECs, we cannot
determine the fate of these progenitor-derived structures
following parturition.
While this work was in progress, Vaillant et al. reported
that CD24+/CD29- cells can form limited mammary struc-
tures in vivo only when co-injected with Matrigel, while the
repopulating ability of CD24+/CD29+ cells is the same with
or without Matrigel co-injection [10]. Jeselsohn et al. also
found that CD24+/CD49flo MECs developed mammary
outgrowths only in the presence of Matrigel [11], whereas
Spike et al. reported that Matrigel could increase the
mammary repopulation activity content of embryonic
mammary cells [43]. These results suggest that the mam-
mary gland contains progenitors that require additional sig-
nals or growth factors to survive or proliferate, and could
explain why the ability of CD24+/CD29lo cells to form out-
growths was missed in earlier studies [4]. Although these
studies demonstrated that CD24+/CD29lo MECs can form
mammary outgrowths following transplant into virgin
females, they did not assess the effects of pregnancy on
the rate (or detection) of repopulation.
Our data show that this Matrigel-dependent outgrowth-
generating ability is restricted to a subpopulation within
the CD24+/CD29lo compartment. Furthermore, the prolif-
eration and development of outgrowths from these cells is
increased by pregnancy. It is possible that Matrigel is
required for the engraftment of H2BGFP+/CD24+/CD29lo
cells in vivo, but based on our data, we conclude that
pregnancy is still the critical trigger for development of
mammary structures able to pass the threshold of de-
tection in most outgrowths.
The existence of mammary progenitors with hormone-
or environment-dependent activity is supported by a recent
and extensive lineage-tracing study, which concluded that
mammary stem cells derive from an embryonic CK14+
lineage, whereas CK8 cells only give rise to luminal progen-
itors [14]. Cells from the CK8+ lineage also can contribute
to alveoli in successive pregnancies, but are unable to form
mammary structures in vivo without co-injection of other
MECs. In another study, Sleeman et al. showed that CD24+
MECs co-transplanted with Matrigel can give rise to mam-
mary outgrowths with a wide range of sizes, suggesting
that mammary stem cells/progenitors with different
in vivo growth potentials exist within the CD24+ com-
partment [13]. These findings, in conjunction with our
data, suggest that the mammary gland contains progeni-
tors that undergo proliferation only when presented
with specific stimuli, such as pregnancy hormones or
paracrine signals from other MECs. Although Matrigel
clearly can supply some signals required for mammary
progenitor survival or proliferation, in our study, preg-
nancy was the primary driver of mammary outgrowths
from H2BGFP+/CD24+/CD29lo cells.
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fiable by MMTVrtTA/H2BGFP expression were verified by
gene expression analysis. By unsupervised hierarchical
clustering, samples from the H2BGFP+ and H2GFP-
CD24+/CD29lo populations segregated independently,
consistent with their functional differences in transplant-
ation experiments. Significantly, genes with critical roles in
mammary development, including Areg, Esr1 and Prlr, were
expressed at lower levels in H2BGFP+/CD24+/CD29e
cells, which suggests that these cells are less differentiated
than H2BGFP-/CD24+/CD29lo MECs. H2BGFP+/CD24+/
CD29lo cells also shared partial gene signatures with
the CD24+/CD29+ (stem cell) and CD24+/CD29lo/CD61+
(luminal progenitor) populations. In particular, genes
expressed at lower levels in the H2BGFP+/CD24+/CD29lo
cells were expressed at low levels in CD24+/CD29+
(stem cell-enriched) MECs, whereas genes expressed at
higher levels in H2BGFP+/CD24+/CD29lo cells were
expressed at higher levels in CD24+/CD29lo/CD61+
MECs. Because H2BGFP expression in the CD24+/CD29lo
population did not correlate with CD61 expression
(Figure S1 in Additional file 1), these results suggest
that H2BGFP+/CD24+/CD29lo cells have an intermediate
phenotype between mammary stem cells and luminal pro-
genitors, as expected for a multipotent progenitor.
We attempted to identify a marker that could separ-
ate the H2BGFP+ and H2BGFP- populations in the
CD24+/CD29lo compartment by FACS, without use of
our transgenic model. To this end, we tested antibodies
against antigens found by the microarray (CD14, AREG,
AlCAM, CD55, CXCL16, CD164, CD138, PRLR) or that
have been identified as potential mammary lineage markers
(CD49b, CD24, Sca-1, c-kit). However, no marker proved
suitable for isolation of the H2BGFP+/CD24+/CD29lo
population (Figure S1 in Additional file 1). The only
notable result was that all H2BGFP+/CD24+/CD29lo
MECs, as well as a significant fraction of H2BGFP-/
CD24+/CD29lo MECs, were found to be CD14+. Other
studies have found that CD14+ MECs demonstrate an
alveolar phenotype in vitro, but the in vivo role of these
cells is currently unknown [8,9].
While this manuscript was in review, Dos Santos and
colleagues used an H2BGFP label retention approach
to isolate an enriched mammary stem cell population
employing the K5 promoter to induce H2BGFP expression
rather than the MMTV promoter. The CD24+/CD29+
subpopulation that was isolated using label retention
was found to have a mammary repopulation frequency
of 1/33, as compared to the 1/70 described by Shackleton
et al. [4]. Transcriptional profiling of these cells led to the
identification of additional cell surface markers CD1d,
CD22, and CD59a that could further purify mammary stem
cells [20]. In our studies, we were unable to find CD24+/
CD29+ MECs with enhanced mammary repopulationabilities, through either MMTVrtTA/H2BGFP expres-
sion or MMTVrtTA/H2BGFP label retention, though
it is possible our ‘chase’ was insufficient in the label re-
tention studies.
It has been hypothesized that the mammary stem cells
responsible for establishing the mammary architecture
during puberty are directly responsible for all subse-
quent mammary proliferation [37,38]. However, our data
suggest that the developing mammary gland contains
multipotent pregnancy-activated progenitors that give
rise to milk-producing mammary structures in vivo. We
conclude that the mammary stem cell hierarchy contains
progenitors not only for different MEC lineages, but also
for the specific functions and structures involved in
lactation. These progenitors are of particular interest
in light of the evidence that early pregnancy can pro-
tect from breast cancer, presumably from a reduction
in the proliferative potential of stem cells and/or the
likelihood that progenitors that are potential targets for ma-
lignant transformation. MECs that proliferate actively in
response to pregnancy might be prone to oncogenesis,
and therefore merit further investigation on both scien-
tific and medical grounds.
Conclusions
We have provided evidence for a multipotent mammary
progenitor present in the glands of pre-pubertal virgin
females, which, when transplanted into the mammary
fat pad, gives rise to milk-producing mammary structures
containing multiple cell lineages at a dramatically higher
frequency during pregnancy. This progenitor population is
distinguished from previously identified mammary lineages
by in vivo function and gene expression analysis, and might
represent a target cell in mammary tumorigenesis. Further
study is required to better elucidate this progenitor’s role in
normal mammary development and oncogenesis.
Additional files
Additional file 1: Figure S1. Candidate markers for separating
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations.
Mammary epithelial cells (MECs) from 4-week-old MMTVrtTA/H2BGFP
females were isolated, stained with a panel of antibodies against surface
proteins, and analyzed by flow cytometry for their ability to distinguish
the H2BGFP+/CD24+/CD29lo (green) and H2BGFP-/CD24+/CD29lo (red)
populations. Markers included previously identified stem cell/progenitor
markers and differentially expressed genes identified from microarray
analyses (see Figure 6). H2BGFP, histone 2B-eGFP; MMTV, mouse
mammary tumor virus promoter; rtTA, reverse tetracycline transactivator.
Additional file 2: Figure S2. Schematic of MMTVrtTA/H2BGFP mice.
The MMTVrtTA strain (tet-on) was crossed with tet-responsive H2BGFP
transgenic mice, resulting in tetracycline/doxycycline-activated, MMTV-driven
expression of H2BGFP. H2BGFP, histone 2B-eGFP; MMTV, mouse mammary
tumor virus promoter; rtTA, reverse tetracycline transactivator.
Additional file 3: Figure S3. Mammary gland scoring system.
Mammary outgrowths were harvested 6 weeks post-transplant, fixed and
stained with Carmine Alum. Mammary glands were scored for outgrowth
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http://breast-cancer-research.com/content/15/4/R65size based on the percentage of the mammary fat pad filled with
epithelium, as indicated.
Additional file 4: Table S1. Mammary outgrowth sizes in limiting dilution
transplants. Size of mammary outgrowths from H2BGFP+/CD24+/CD29+
(a, e), H2BGFP-/CD24+/CD29+ (b, f), H2BGFP+/CD24+/CD29lo (c, g, i) and
H2BGFP-/CD24+/CD29lo (d, h, j) populations in virgin mice (a-d, i) and
pregnant mice (e-h, j). H2BGFP, histone 2B-eGFP.
Additional file 5: Hierarchical clustering of probes found to be
significantly differentially expressed between the CD29 +
CD24- GFP + versus CD29 + CD24- GFP- populations.
Additional file 6: Differentially expressed genes between the
H2BGFP+/CD24+/CD29lo and H2BGFP-/CD24+/CD29lo populations
compared with those found in a publicly available data set
consisting of isolated mammary stem cell-enriched (MaSC), luminal
progenitor (lum prog) and mature luminal mammary epithelial cell
(lum mature MEC) populations. H2BGFP, histone 2B-eGFP.
Additional file 7: Figure S4. Cytospins of MMTVrtTA/H2BGFP
populations. MMTVrtTA/H2BGFP mammary epithelial cell (MEC)
populations were isolated by fluorescence-activated cell sorting (FACS),
cytospun onto slides, fixed and immunostained for mammary lineage
markers and microarray hits. The percentage of cells from each
subpopulation that stain positive for each marker is indicated. H2BGFP,
histone 2B-eGFP; MMTV, mouse mammary tumor virus promoter; rtTA,
reverse tetracycline transactivator.
Abbreviations
bp: Base pair; BSA: Bovine serum albumin; CI: Confidence interval; DAPI:
4',6-diamidino-2-phenylindole; DMEM: Dulbecco’s modified Eagle’s medium;
EGF: Epidermal growth factor; ER: Estrogen receptor; FACS: Fluorescence-
activated cell sorting; FBS: Fetal bovine serum; FDR: False discovery rate;
GFP: Green flourescent protein; GR: Glucocorticoid receptor; H2BGFP: Histone
2B enhanced GFP; MaSC: Mammary stem cell; MEC: Mammary epithelial cell;
MMTV: Mouse mammary tumor virus promoter; MRU: Mammary
repopulating unit; PBS: Phosphate-buffered saline; PR: Progesterone receptor;
rtTA: Reverse tetracycline transactivator; TEB: Terminal end bud.
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